AC Immune Reports Q1 2026 Financial Results and Clinical Pipeline Progress

AC Immune SA (NASDAQ: ACIU) reported its Q1 2026 financial results and provided a comprehensive corporate update. As of March 31, 2026, the company held CHF 74.8 million in total cash resources, which it expects will provide a cash runway into Q4 2027. The net loss for the quarter was CHF 14.8 million, an improvement from CHF 19.0 million in Q1 2025, driven by pipeline focus initiatives and reduced R&D spending. Key clinical progress includes the initiation of the final AD4 cohort in the Phase 1b/2 ABATE trial for ACI-24, triggering a $12 million milestone payment from Takeda. The company also dosed the first subjects in a Phase 1 trial for ACI-19764, a brain-penetrant NLRP3 inhibitor. Additionally, AC Immune amended its Tau collaboration with Eli Lilly, receiving a CHF 10 million upfront payment in Q2 2026. Multiple clinical readouts are anticipated in H2 2026, including final data from Part 1 of the Phase 2 VacSYn trial for ACI-7104 in Parkinson’s disease and Phase 1 results for ACI-19764.